CELLECTIS is a biotechnology company founded by three scientists from Institut Pasteur : Doctors André Choulika, David Sourdive and Arnaud Perrin. CELLECTIS SA is specialized in rational genome engineering in order to improve human, animal and plant health.
CELLECTIS is developing unique, state-of-the-art technologies that are revolutionizing genome engineering. These technologies are based on Meganucleases™, a new class of "molecular scissors". These new tools allow reliable and precise modifications of the genetic program of any living organism, from bacteria to humans. Fine surgery of DNA in vivo, without addition of viral or other foreign genomes, is now tending to reality.
CELLECTIS controls an outstanding patent portfolio covering nine technologies. They have potential applications in treatment of viral and hereditary diseases, in the processes of validation and production of medicines, as well as in the improvement of animal and plant species. The wide spectrum of potential applications opens many opportunities for partnerships with both the pharmaceutical and food industries.
CELLECTIS SA is the third start-up company to be hosted within the Institut Pasteur campus. The company will have a privileged access to one of the most important technological platform in life sciences in the world. CELLECTIS is setting up close collaborations with internationally renowned laboratories. Institut Pasteur is now a shareholder in the company along with the scientists involved in the project.
CELLECTIS SA is at the cutting edge of the Meganuclease™ technology and aims at a leading position in the field of rational genome engineering within five years.
To find out more : CELLECTIS , Méganucleases
Contact : Press Office, Institut Pasteur tel: 33 (0) 1 45 68 81 46